Maria T. Rodriguez-Plata
Research Subjects
Maria T. Rodriguez-Plata has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Adam Peall
Charnwood Discovery, Loughborough, United Kingdom
17 shared publications - Alba Guarné
McGill University
17 shared publications - Alberto Bardelli
IFOM ETS - The AIRC Institute of Molecular Oncology, Milan, Italy
17 shared publications - Alexia Hervieu
NeoPhore Ltd, Altrincham, United Kingdom
17 shared publications - Charles Nichols
Charles River Laboratories, Saffron Walden, United Kingdom
17 shared publications - Daniel J.H. Nightingale
Charles River Laboratories, Saffron Walden, United Kingdom
17 shared publications
Latest Publications
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Methods 1 from Pharmacologic Inhibition of PMS2 Induces MMR Deficiency and Response to Immune Checkpoint Blockade
Chemistry methods; protein production, purification and crystallisation methods; biochemical and nanoBRET assay protocols; target engagement and cysteinome profiling methods
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Methods 1 from Pharmacologic Inhibition of PMS2 Induces MMR Deficiency and Response to Immune Checkpoint Blockade
Chemistry methods; protein production, purification and crystallisation methods; biochemical and nanoBRET assay protocols; target engagement and cysteinome profiling methods
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from Pharmacologic Inhibition of PMS2 Induces MMR Deficiency and Response to Immune Checkpoint Blockade
Datasets related to Supplementary Figures S2A, S2C, S2D, and S9A-J; data related to main Figure 5 and detailed PRM-MS Methods
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from Pharmacologic Inhibition of PMS2 Induces MMR Deficiency and Response to Immune Checkpoint Blockade
Datasets related to Supplementary Figures S2A, S2C, S2D, and S9A-J; data related to main Figure 5 and detailed PRM-MS Methods
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S10 from Pharmacologic Inhibition of PMS2 Induces MMR Deficiency and Response to Immune Checkpoint Blockade
NP1867-pretreated murine breast cancer cells (TS/A) injected in immuno-competent mice display immune mediated regression
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S10 from Pharmacologic Inhibition of PMS2 Induces MMR Deficiency and Response to Immune Checkpoint Blockade
NP1867-pretreated murine breast cancer cells (TS/A) injected in immuno-competent mice display immune mediated regression
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Video 1 from Pharmacologic Inhibition of PMS2 Induces MMR Deficiency and Response to Immune Checkpoint Blockade
Supplementary Video 1 from Pharmacologic Inhibition of PMS2 Induces MMR Deficiency and Response to Immune Checkpoint Blockade
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Video 1 from Pharmacologic Inhibition of PMS2 Induces MMR Deficiency and Response to Immune Checkpoint Blockade
Supplementary Video 1 from Pharmacologic Inhibition of PMS2 Induces MMR Deficiency and Response to Immune Checkpoint Blockade
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Pharmacologic Inhibition of PMS2 Induces MMR Deficiency and Response to Immune Checkpoint Blockade
Cell-based PMS2 inhibition by NP1867
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Pharmacologic Inhibition of PMS2 Induces MMR Deficiency and Response to Immune Checkpoint Blockade
Cell-based PMS2 inhibition by NP1867
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 and 2 from Pharmacologic Inhibition of PMS2 Induces MMR Deficiency and Response to Immune Checkpoint Blockade
Table 1: Biochemical characterization of Fragment 1, NP1867, and NP2567. Table 2: Data collection and refinement statistics (molecular replacement)
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 and 2 from Pharmacologic Inhibition of PMS2 Induces MMR Deficiency and Response to Immune Checkpoint Blockade
Table 1: Biochemical characterization of Fragment 1, NP1867, and NP2567. Table 2: Data collection and refinement statistics (molecular replacement)
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S8 from Pharmacologic Inhibition of PMS2 Induces MMR Deficiency and Response to Immune Checkpoint Blockade
Chronic treatment with NP1867 enhances the immunological responsiveness of CT26 tumours to anti-PD-1 therapy in vivo.
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S8 from Pharmacologic Inhibition of PMS2 Induces MMR Deficiency and Response to Immune Checkpoint Blockade
Chronic treatment with NP1867 enhances the immunological responsiveness of CT26 tumours to anti-PD-1 therapy in vivo.
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Pharmacologic Inhibition of PMS2 Induces MMR Deficiency and Response to Immune Checkpoint Blockade
PMS2 ATP binding site homology, chemical structures and protein-ligand crystal structure of Fragment 1 in PMS2
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Pharmacologic Inhibition of PMS2 Induces MMR Deficiency and Response to Immune Checkpoint Blockade
PMS2 ATP binding site homology, chemical structures and protein-ligand crystal structure of Fragment 1 in PMS2
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Pharmacologic Inhibition of PMS2 Induces MMR Deficiency and Response to Immune Checkpoint Blockade
NP1867: A potent and selective covalent PMS2 ligand
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Pharmacologic Inhibition of PMS2 Induces MMR Deficiency and Response to Immune Checkpoint Blockade
NP1867: A potent and selective covalent PMS2 ligand
- Open Access
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Data from Pharmacologic Inhibition of PMS2 Induces MMR Deficiency and Response to Immune Checkpoint Blockade
DNA mismatch repair (MMR) detects and corrects postreplicative DNA alterations; it is deregulated in up to 20% of human cancers. MMR-deficient (MMR-d) cancers display increased tumor mutational burden (TMB) and microsatellite instability (MSI) and are eligible for checkpoint inhibitor (CPI) immunotherapy which commonly elicits durable responses. We reasoned that pharmacologic blockade of MMR could broaden the patient population eligible for immunotherapy. Here, we reveal MMR protein PMS2 as a druggable target and describe the discovery and characterization of first-in-class small-molecule MMR pathway modulator NP1867. In vitro treatment of murine cancer cells abrogates MMR function and elicits an MMR-d genotype, including increased TMB, MMR-d mutational signatures, and MSI-high (MSI-H) status. Inoculation of syngeneic immunocompetent mice with cancer cells pretreated with NP1867 leads to CPI sensitivity, tumor growth delay, and complete responses. For the first time, we demonstrate pharmacologic targeting of MMR to proactively rewire the tumor–host relationship for therapeutic purposes. Significance:We present the discovery and characterization of NP1867, a selective covalent small-molecule inhibitor of MMR protein PMS2. Pharmacologic blockade of PMS2 leads to an MMR-deficient genotype characterized by increased TMB, enriched MMR-d mutational signatures, and MSI-H status. Treatment with NP1867 converts immunoresistant, MMR-proficient cancers into CPI-responsive tumors.See related commentary by Bernards, p. 1486
- 3 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Pharmacologic Inhibition of PMS2 Induces MMR Deficiency and Response to Immune Checkpoint Blockade
DNA mismatch repair (MMR) detects and corrects postreplicative DNA alterations; it is deregulated in up to 20% of human cancers. MMR-deficient (MMR-d) cancers display increased tumor mutational burden (TMB) and microsatellite instability (MSI) and are eligible for checkpoint inhibitor (CPI) immunotherapy which commonly elicits durable responses. We reasoned that pharmacologic blockade of MMR could broaden the patient population eligible for immunotherapy. Here, we reveal MMR protein PMS2 as a druggable target and describe the discovery and characterization of first-in-class small-molecule MMR pathway modulator NP1867. In vitro treatment of murine cancer cells abrogates MMR function and elicits an MMR-d genotype, including increased TMB, MMR-d mutational signatures, and MSI-high (MSI-H) status. Inoculation of syngeneic immunocompetent mice with cancer cells pretreated with NP1867 leads to CPI sensitivity, tumor growth delay, and complete responses. For the first time, we demonstrate pharmacologic targeting of MMR to proactively rewire the tumor–host relationship for therapeutic purposes. Significance:We present the discovery and characterization of NP1867, a selective covalent small-molecule inhibitor of MMR protein PMS2. Pharmacologic blockade of PMS2 leads to an MMR-deficient genotype characterized by increased TMB, enriched MMR-d mutational signatures, and MSI-H status. Treatment with NP1867 converts immunoresistant, MMR-proficient cancers into CPI-responsive tumors.See related commentary by Bernards, p. 1486